Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine

Pharmacopsychiatry

Volumn 30, Issue 6, 1997, Pages 274-275

  Azaz Livshits, T L T ^a   Danenberg, H D ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CLONAZEPAM; ENALAPRIL; FLUOXETINE; NIFEDIPINE; SEROTONIN UPTAKE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR EFFECT; CASE REPORT; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MUSCLE WEAKNESS; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; TACHYCARDIA;

EID: 0031453309     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979508     Document Type: Article

References (16)

1. Borys, D. J., S. C Setzer, L. J. Ling, J. J. Reisdorf, L. C. Day, et al.: The effects of fluoxetine in the overdose patient. J. Toxicol. - Clin. Toxicol. 28 (1990) 331-340
2. Britton, J. W., E. L. So: Selection of antiepileptic drugs: a practical approach. Mayo Clin. Proc 71 (1996) 778-786
3. Dellatle, C. L.: Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Clin. Psychiatry 55 (1994) 38-45
4. Gardner, S. F., W. F. Rutherford, M. A. Munger, E. A. Panacek: Drug-induced supraventricular tachycardia: a case report of fluoxetine. Ann. Emerg. Med. 20 (1991) 194-197
5. Horton, R. C., R. S. Bosner: Cyclosporine-Fluoxetine Interaction. BMJ 311 (1995) 422
6. Kleinblosem, C. H., P. van-Brummelen, H. Faber, M. Danhnf, N. P. Vermeulen, D. D. Breimer: Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem. Pharmacol. 33 (1984) 3721-3724
7. Lobo, J., D. B. Jack, M. J. Kendal: The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers. Eur. J. Clin. Pharmacol. 30 (1986) 57-60
8. Marchiando, R. J., M. D. Cook: Probable terfenadine-fluoxetine-associated cardiac toxicity. Ann. Pharmacotherapy 29 (1995) 937-938
9. Martindale (1): The Extra Pharmacopoeia, 31th ed. The Pharmaceutical Press, London (1996) 314-316
10. Martindale (2): The Extra Pharmacopoeia, 31th ed. The Pharmaceutical Press, London (1996) 916-921
11. Pollak, P. T., I. S. Sketris, S. L. Mackenzie, T. J. Hewlett: Delirium probably induced by clarithromycin in a aptient receiving fluoxetine. Ann. Pharmacotherapy 29 (1995) 486-488
12. Soons, P. A., H. C. Schoemaker, A. F. Cohen, D. D. Breimer: Intraindividual variabilityn in nifedipine pharmacokinetics and effects in healthy subjects. J Clin. Pharmacol. 32 (1992) 324-331
13. Spina, E., A. Avernosos, A. M. Pollicino, A. P. Caputi, et al.: Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther. Drug Monit. 15 (1993) 247
14. Sternbach, H.: Fluoxetine-Associated potentiation of calcium-channel blockers. J. Clin. Psychopharmacol. 11 (1991) 390-391
15. Strouse, T. B., L. A. Fairbranks, C. E. Skotzko, F. I. Fawzy: Fluoxetine and cyclosporine in organ transplantation: failure to detect significant drug interactions or adverse clinical events in depressed organ recipients. Psychosomatics 37 (1996) 23-30
16. Taylor, D., M. Lader: Cytochromes and psychotropic drug interactions. Br. J. Psychiatry 168 (1996) 529-532